PMN (PMN) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PMN (PMN) Healthcare & Pipeline Overview

ProMIS Neurosciences, Inc., a Canadian biotechnology firm with a $19.5M market cap, pioneers precision medicine for neurodegenerative diseases. Utilizing its proprietary ProMIS and Collective Coordinates algorithms, the company develops targeted monoclonal antibodies like PMN310, PMN267, and PMN442, addressing Alzheimer's, ALS, and MSA, positioning it as a high-risk, high-reward player in the biotechnology sector.

What Is the Investment Thesis for PMN?

ProMIS Neurosciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's proprietary discovery platform, targeting misfolded proteins in neurodegenerative diseases, offers potential for breakthrough therapies. Key value drivers include the successful development and clinical validation of its lead product candidates, PMN310 for Alzheimer's, PMN267 for ALS, and PMN442 for MSA. The company's small market capitalization of $19.5M reflects the early stage of its pipeline and the inherent risks associated with biotechnology development. Upcoming clinical trial results for PMN310 and PMN442 represent significant catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional financing. The company's beta of -0.15 suggests a low correlation with overall market movements, potentially offering diversification benefits. Successful execution of its clinical programs and strategic partnerships could drive substantial value appreciation, while setbacks could significantly impact the company's prospects.

Based on FMP financials and quantitative analysis

PMN Key Highlights

ProMIS Neurosciences focuses on precision medicine solutions for neurodegenerative diseases, including Alzheimer's, ALS, and MSA.

• The company's proprietary discovery platform uses ProMIS and Collective Coordinates algorithms to identify novel drug targets.
• Lead product candidates include PMN310 (Alzheimer's), PMN267 (ALS), and PMN442 (MSA), all monoclonal antibodies targeting toxic protein aggregates.
• ProMIS Neurosciences has a small market capitalization of $19.5M, reflecting its early-stage development and high-risk profile.
• The company's headquarters are located in Toronto, Canada, with a small team of 7 employees.

Who Are PMN's Competitors?

PMN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PMN's Key Strengths?

Proprietary discovery platform targeting misfolded proteins.

• Focus on precision medicine for neurodegenerative diseases.
• Lead product candidates with potential for breakthrough therapies.
• Experienced management team with expertise in drug development.

What Are PMN's Weaknesses?

Small market capitalization and limited financial resources.

• Early-stage development pipeline with high clinical trial risk.
• Dependence on partnerships for clinical development and commercialization.
• Limited commercial infrastructure.

What Could Drive PMN Stock Higher?

Clinical trial results for PMN310 in Alzheimer's disease.

• Clinical trial results for PMN442 in Multiple System Atrophy (MSA).
• Strategic partnerships and collaborations for clinical development and commercialization.
• Expansion of intellectual property portfolio through patent filings.
• Advancements in the company's proprietary discovery platform.

What Are the Key Risks for PMN?

Financial-distress signal — its Altman Z-Score of -3.60 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures and regulatory hurdles.
• Competition from larger pharmaceutical companies with greater resources.
• Patent expiration and generic competition.
• Dependence on external funding to support research and development.
• Economic downturn and reduced healthcare spending.

What Are the Growth Opportunities for PMN?

• Advancement of PMN310 for Alzheimer's Disease: Alzheimer's disease represents a substantial market opportunity, with millions affected globally. PMN310, ProMIS's lead monoclonal antibody targeting toxic oligomers in AD, has the potential to address a critical unmet need. Successful completion of clinical trials and regulatory approval could position PMN310 as a significant player in the AD treatment landscape. The Alzheimer's Association estimates that in 2026, 7.26 million Americans age 65 and older are living with Alzheimer's. This represents a huge market opportunity if PMN310 is successful.
• Development of PMN267 for ALS: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. PMN267, targeting superoxide dismutase 1 and TAR-DNA binding protein 43, offers a novel approach to address the underlying causes of ALS. Positive preclinical and clinical data could drive significant interest and investment in PMN267. The ALS market is projected to grow, driven by increasing awareness and the need for effective therapies. The ALS Association estimates that approximately 5,000 people in the U.S. are diagnosed with ALS each year.
• Expansion into Parkinson's Disease and Lewy Body Dementia: PMN267's potential application in Parkinson's disease and Lewy body dementia expands its therapeutic scope. These neurodegenerative disorders share common pathological features, including alpha-synuclein aggregation. By targeting alpha-synuclein, PMN267 could offer a disease-modifying approach for these conditions. The Parkinson's and Lewy body dementia markets are substantial and growing, driven by an aging population. The Parkinson's Foundation estimates that nearly one million people in the U.S. will be living with Parkinson's disease by 2030.
• Advancement of PMN442 for Multiple System Atrophy (MSA): Multiple system atrophy (MSA) is a rare and rapidly progressive neurodegenerative disorder with no effective treatments. PMN442, targeting toxic a-syn oligomers and seeding fibrils in MSA, represents a promising therapeutic strategy. Successful development of PMN442 could provide a significant benefit to patients with MSA and establish ProMIS as a leader in this niche market. The MSA Coalition estimates that approximately 15,000-20,000 individuals in the U.S. have MSA.
• Strategic Partnerships and Collaborations: ProMIS can leverage strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and infrastructure, mitigating the risks associated with drug development. These partnerships can also enhance the company's credibility and visibility within the biotechnology industry. Successful partnerships could drive significant value appreciation for ProMIS.

What Are PMN's Competitive Advantages?

• Proprietary discovery platform (ProMIS and Collective Coordinates algorithms) that identifies novel drug targets.
• Patent protection on its lead product candidates and platform technology.
• Expertise in targeting misfolded proteins in neurodegenerative diseases.
• First-mover advantage in developing precision medicine solutions for specific disease epitopes.

What Does PMN Do?

ProMIS Neurosciences, Inc., founded in 2004 and headquartered in Toronto, Canada, is a biotechnology company dedicated to discovering and developing precision medicine solutions for neurodegenerative diseases. Originally incorporated as Amorfix Life Sciences Ltd., the company rebranded to ProMIS Neurosciences, Inc. in July 2015, marking a strategic shift towards its current focus. The company's core technology lies in its proprietary discovery platform, which leverages the ProMIS and Collective Coordinates algorithms. These algorithms are designed to predict novel targets, specifically disease-specific epitopes, on the molecular surface of misfolded proteins. This approach allows ProMIS to develop highly targeted therapies for diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). ProMIS's lead product candidates include PMN310, a monoclonal antibody (mAb) targeting toxic oligomers in AD; PMN267, aimed at superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. These product candidates represent the company's commitment to addressing significant unmet needs in the treatment of neurodegenerative disorders. With a small team of 7 employees, ProMIS operates primarily in Canada, focusing on research and development activities to advance its pipeline of precision medicine solutions.

What Products and Services Does PMN Offer?

• Discovers and develops precision medicine solutions.
• Targets neurodegenerative diseases like Alzheimer's, ALS, and MSA.
• Utilizes proprietary ProMIS and Collective Coordinates algorithms.
• Predicts novel targets on misfolded proteins.
• Develops monoclonal antibodies (mAbs) for specific disease epitopes.
• Focuses on disease-specific epitopes on misfolded proteins.

How Does PMN Make Money?

• Develops proprietary drug candidates targeting neurodegenerative diseases.
• Out-licenses or partners with larger pharmaceutical companies for clinical development and commercialization.
• Generates revenue through milestone payments, royalties, and licensing fees.

What Industry Does PMN Operate In?

ProMIS Neurosciences operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for neurodegenerative disease treatments is substantial and growing, driven by an aging global population and increasing prevalence of conditions like Alzheimer's and Parkinson's. The company's focus on precision medicine and targeting misfolded proteins differentiates it from traditional approaches. Key competitors include larger pharmaceutical companies and specialized biotechnology firms developing therapies for similar indications. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships to navigate the complex regulatory landscape and commercialization challenges. The global neurodegenerative disease market is projected to reach $48.3 billion by 2026, reflecting the significant unmet need and commercial opportunity.

Who Are PMN's Key Customers?

• Pharmaceutical companies seeking novel drug candidates for neurodegenerative diseases.
• Patients suffering from Alzheimer's, ALS, MSA, and other neurodegenerative disorders.
• Healthcare providers who prescribe and administer treatments for these conditions.

Key Financial Metrics

Return on assets is -74.5%, showing how much profit it generates from its asset base. A current ratio of 7.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -31.1%, the inverse of the P/E and a quick read on earnings relative to price.

PMN (PMN) Valuation Context

Valued at $19.5M, PMN is classified as a micro-cap stock. Relative to its peer group, PMN's quantitative score of 52/100 is below the peer average of 82/100.

Company Profile

PMN operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Neil K. Warma. PMN has traded publicly since 2007.

PMN's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.60 places it in the distress zone, a signal of elevated financial risk.

PMN has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 76.2% above estimates on average.

Wall Street analysts project PMN revenue of about $0 for fiscal 2026, with EPS near $-5.28.

PMN Financials

PMN Latest News

PMN Analyst Consensus

PMN MoonshotScore

What Investors Ask About PMN (PMN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources